MX2021001952A - Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met. - Google Patents

Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met.

Info

Publication number
MX2021001952A
MX2021001952A MX2021001952A MX2021001952A MX2021001952A MX 2021001952 A MX2021001952 A MX 2021001952A MX 2021001952 A MX2021001952 A MX 2021001952A MX 2021001952 A MX2021001952 A MX 2021001952A MX 2021001952 A MX2021001952 A MX 2021001952A
Authority
MX
Mexico
Prior art keywords
sup
tam
inhibitors
pyrazolo
pyridine compounds
Prior art date
Application number
MX2021001952A
Other languages
English (en)
Inventor
John Gaudino
Ellen Laird
Shelley Allen
Ronald Jay Hinklin
Qian Zhao
Adam Cook
Oren T Mcnulty
Patrick Barbour
Joshua Dahlke
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2021001952A publication Critical patent/MX2021001952A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula I: (ver Fórmula) y estereoisómeros, tautómeros y sales de los mismos farmacéuticamente aceptables, en donde R1, R2, R9, X1 y 10 G son como se definen en la presente, los cuales son inhibidores de una o más cinasas TAM y/o cinasa c-Met, y son útiles en el tratamiento y prevención de enfermedades las cuales pueden ser tratadas con un inhibidor de cinasa TAM y/o un inhibidor de cinasa c-Met.
MX2021001952A 2018-08-30 2019-08-29 Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met. MX2021001952A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724829P 2018-08-30 2018-08-30
US201962858686P 2019-06-07 2019-06-07
PCT/US2019/048701 WO2020047184A1 (en) 2018-08-30 2019-08-29 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES

Publications (1)

Publication Number Publication Date
MX2021001952A true MX2021001952A (es) 2021-04-19

Family

ID=67928919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001952A MX2021001952A (es) 2018-08-30 2019-08-29 Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met.

Country Status (24)

Country Link
US (2) US11104676B2 (es)
EP (1) EP3843850B1 (es)
JP (2) JP6970859B2 (es)
KR (1) KR20210049898A (es)
CN (1) CN112930215A (es)
AU (3) AU2019330017B2 (es)
BR (1) BR112021002722A2 (es)
CA (1) CA3110502C (es)
CL (1) CL2021000467A1 (es)
CO (1) CO2021002651A2 (es)
CR (1) CR20210098A (es)
CU (1) CU20210015A7 (es)
DO (1) DOP2021000038A (es)
EC (1) ECSP21012498A (es)
IL (1) IL281127B2 (es)
MA (1) MA53487A (es)
MX (1) MX2021001952A (es)
NI (1) NI202100007A (es)
PE (1) PE20211779A1 (es)
PH (1) PH12021500017A1 (es)
SG (1) SG11202101148UA (es)
TW (1) TW202024071A (es)
UY (1) UY38349A (es)
WO (1) WO2020047184A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210049862A (ko) * 2018-08-24 2021-05-06 난징 트렌스테라 바이오사이언스즈 컴퍼니 리미티드 일종의 신형 퀴놀린 유도체 억제제
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物
EP4029862A4 (en) * 2019-09-06 2023-10-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences CONNECTION WITH AXL AND C-MET KINASE INHIBITORY ACTIVITY, THEIR PREPARATION AND USE
WO2021057782A1 (zh) * 2019-09-24 2021-04-01 南京药捷安康生物科技有限公司 杂环衍生物及其用途
JP7181325B2 (ja) * 2020-03-03 2022-11-30 アレイ バイオファーマ インコーポレイテッド がんを処置するための方法
EP4319748A1 (en) * 2021-04-09 2024-02-14 Tachyon Therapeutics, Inc. Treatment of cancer with kdm4 inhibitors
WO2023002360A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Solid forms and formulations of an inhibitor of tam and c-met kinases
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN115850301A (zh) * 2021-09-24 2023-03-28 中山医诺维申新药研发有限公司 吡唑酮类化合物及其组合物和用途
CA3236956A1 (en) * 2021-11-05 2023-05-11 Haihe Biopharma Co., Ltd. Solid dispersion, preparation method therefor, and solid formulation comprising same
WO2023078408A1 (zh) * 2021-11-05 2023-05-11 上海海和药物研究开发股份有限公司 含met受体酪氨酸激酶抑制剂的药物组合及应用
US11753395B2 (en) 2021-12-16 2023-09-12 Kinnate Biopharma Inc. Inhibitors of MET kinase
WO2023125803A1 (zh) * 2021-12-29 2023-07-06 北京鞍石生物科技有限责任公司 杂芳环氮氧化合物及其制备方法和应用
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
JP5368701B2 (ja) 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド c−Metモジュレーター及び使用方法
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
JP2009529047A (ja) * 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
WO2013032797A2 (en) * 2011-08-26 2013-03-07 New Hope R & D Bioscience, Inc. Oxetane 3,3-dicarboxamide compounds and methods of making and using same
JP2014534949A (ja) * 2011-09-19 2014-12-25 ジェネンテック, インコーポレイテッド C−metアンタゴニストおよびb−rafアンタゴニストを含む組合せ処置
KR20140090678A (ko) * 2011-11-14 2014-07-17 세파론, 인코포레이티드 AXL 및 c-MET 키나제 억제제로서의 우라실 유도체
JP2016527274A (ja) 2013-08-02 2016-09-08 イグナイタ インコーポレイテッド AXL/cMET阻害剤を単独または他の薬剤と組み合わせて用いて各種がんを治療する方法
HUE037579T2 (hu) * 2013-12-26 2018-09-28 Ignyta Inc Pirazolo[1,5-a]piridin-származékok és módszerek alkalmazásukra
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
KR101829998B1 (ko) 2015-11-04 2018-02-19 롬엔드하스전자재료코리아유한회사 착색 감광성 수지 조성물 및 이를 이용한 차광성 스페이서
SG10202009423QA (en) * 2016-03-28 2020-11-27 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
US20190269666A1 (en) 2016-07-29 2019-09-05 Eli Lilly And Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN109689056A (zh) 2016-08-01 2019-04-26 亚尼塔公司 用于治疗癌症的组合
WO2018039275A1 (en) 2016-08-24 2018-03-01 Ignyta, Inc. Combinations for the treatment of cancer
JP2019536771A (ja) 2016-11-16 2019-12-19 イーライ リリー アンド カンパニー エクソン14スキッピング変異またはエクソン14スキッピング表現型を有する癌の治療
CN108250200A (zh) 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN111372925B (zh) 2017-11-24 2022-09-02 南京明德新药研发有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
WO2019113190A1 (en) 2017-12-07 2019-06-13 Array Biopharma Inc. Bicyclic fused pyridine compounds as inhibitors of tam kinases

Also Published As

Publication number Publication date
CA3110502C (en) 2023-10-03
CN112930215A (zh) 2021-06-08
TW202024071A (zh) 2020-07-01
IL281127B1 (en) 2023-12-01
AU2022221514A1 (en) 2022-09-22
KR20210049898A (ko) 2021-05-06
MA53487A (fr) 2021-12-08
AU2019330017A1 (en) 2021-03-04
PH12021500017A1 (en) 2021-09-13
US20230011441A1 (en) 2023-01-12
US11104676B2 (en) 2021-08-31
JP7337133B2 (ja) 2023-09-01
ECSP21012498A (es) 2021-03-31
CR20210098A (es) 2021-07-01
BR112021002722A2 (pt) 2021-08-10
US20200079770A1 (en) 2020-03-12
US11780835B2 (en) 2023-10-10
EP3843850A1 (en) 2021-07-07
SG11202101148UA (en) 2021-04-29
DOP2021000038A (es) 2021-04-15
PE20211779A1 (es) 2021-09-08
EP3843850B1 (en) 2023-11-15
AU2022202946A1 (en) 2022-05-26
UY38349A (es) 2020-03-31
CU20210015A7 (es) 2021-10-12
AU2022202946B2 (en) 2023-08-03
JP2022009720A (ja) 2022-01-14
NI202100007A (es) 2021-06-22
WO2020047184A1 (en) 2020-03-05
IL281127A (en) 2021-04-29
CO2021002651A2 (es) 2021-03-08
CL2021000467A1 (es) 2021-10-22
AU2019330017B2 (en) 2022-05-26
AU2022221514B2 (en) 2023-11-02
IL281127B2 (en) 2024-04-01
JP2021527114A (ja) 2021-10-11
CA3110502A1 (en) 2020-03-05
JP6970859B2 (ja) 2021-11-24

Similar Documents

Publication Publication Date Title
CR20210098A (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX2017013797A (es) Inhibidor de janus quinasa.
UA106054C2 (uk) ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИМІДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ TРK-КІНАЗИ
WO2012158413A3 (en) Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
EA202190393A1 (ru) СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TAM- И Met-КИНАЗ
MY156466A (en) Aminothiazoles and their uses
EA201990939A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA201990940A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos.
UA100999C2 (ru) Аминотиазолы и их применение